530
Views
0
CrossRef citations to date
0
Altmetric
Research Article

An Evaluation of Pharmacists‘ Expectations Towards Pharmacogenomics

, , , , , , , & show all
Pages 165-175 | Published online: 17 Jan 2013

References

  • Venter JC , AdamsMD, MyersEW et al. The sequence of the human genome. Science 291(5507) , 1304–1351 (2001).
  • Frazer KA , BallingerDG, CoxDR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164) , 851–861 (2007).
  • 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature467(7319) , 1061–1073 (2010).
  • Mallal S , PhillipsE, CarosiG et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358(6) , 568–579 (2008).
  • Amado RG , WolfM, PeetersM et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10) , 1626–1634 (2008).
  • Scott SA , SangkuhlK, GardnerEE et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90(2) , 328–332 (2011).
  • Johnson JA , GongL, Whirl-CarrilloM et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4) , 625–629 (2011).
  • Feero WG , KuoGM, JenkinsJF, RackoverMA. Pharmacist education in the era of genomic medicine. J. Am. Pharm. Assoc. (2003) , e113–e121 (2012).
  • Cavallari LH , OverholserBR, AndersenD et al. Recommended basic science foundation necessary to prepare pharmacists to manage personnalized pharmacotherapy. Pharmacotherapy 30 , e228–e235 (2010).
  • Dion-Labrie M , FortinMC, HebertMJ, DoucetH. The use of personalized medicine for patient selection for renal transplantation: Physicians‘ views on the clinical and ethical implications. BMC Med. Ethics11 , 5 (2010).
  • Fargher EA , EddyC, NewmanW et al. Patients‘ and healthcare professionals‘ views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8(11) , 1511–1519 (2007).
  • Voora D , GageBF. Is primary care ready for pharmacogenetics? Pharmacogenomics7(1) , 1–3 (2006).
  • Rogausch A , PrauseD, SchallenbergA, BrockmollerJ, HimmelW. Patients‘ and physicians‘ perspectives on pharmacogenetic testing. Pharmacogenomics7(1) , 49–59 (2006).
  • Finegold P , MathiesonK, HolmesL et al. Is the UK public ready for genetic medicine? Per. Med. 5 , 65–76 (2008).
  • Roederer MW , Van Riper M, Valgus J, Knafl G, McLeod H. Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. Per. Med.9(1) , 19–27 (2011).
  • McCullough KB , FormeaCM, BergKD et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am. J. Pharm. Educ. 75(3) , 51 (2011).
  • Bonter K , DesjardinsC, CurrierN, PunJ, AshburyFD. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open1(1) , e000110 (2011).
  • Haddy CA , WardHM, AngleyMT, MckinnonRA. Consumers‘ views of pharmacogenetics: a qualitative study. Res. Social Adm. Pharm.6(3) , 221–231 (2010).
  • Stanek EJ , SandersCL, TaberKA et al. Adoption of pharmacogenomic testing by us physicians: Results of a nationwide survey. Clin. Pharm. Ther. 91(3) , 450–458 (2012).
  • Haga SB , O‘DanielJM, TindallGM, LipkusIR, AgansR. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J.12(3) , 197–204 (2012).
  • Laegsgaard MM , MorsO. Psychiatric genetic testing: attitudes and intentions among future users and providers. Am. J. Med. Genet. B Neuropsychiatr. Genet.147(3) , 375–384 (2008).
  • Nielsen LF , MoldrupC. The diffusion of innovation: factors influencing the uptake of pharmacogenetics. Community Genet.10(4) , 231–241 (2007).
  • Allegra CJ , JessupJM, SomerfieldMR et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12) , 2091–2096 (2009).
  • Guttmacher AE , PorteousME, McInerneyJD. Educating health-care professionals about genetics and genomics. Nat. Rev. Genet.8(2) , 151–157 (2007).
  • Gurwitz D , WeizmanA, RehaviM. Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol. Sci.24(3) , 122–125 (2003).
  • Murphy JE , GreenJS, AdamsLA, SquireRB, KuoGM, McKayA. Pharmacogenomics in the curricula of colleges and schools of pharmacy in the united states. Am. J Pharm. Educ.74(1) , 7 (2010).
  • Green JS , O‘BrienTJ, ChiappinelliVA, HarralsonAF. Pharmacogenomics instruction in US and canadian medical schools: implications for personalized medicine. Pharmacogenomics11(9) , 1331–1340 (2010).
  • Dodson C , Van Riper M. Analysis of clinicians‘ attitudes towards pharmacogenomics. Per. Med.8(5) , 533–540 (2011).
  • Relling MV , AltmanRB, GoetzMP, EvansWE. Clinical implementation of pharmacogenomics. Overcoming genetic exceptionalism. Lancet Oncol.11(6) , 507–509 (2010).
  • Crews KR , HicksJK, PuiCH, RellingMV, EvansWE. Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther.92(4) , 467–475 (2012).
  • Martin MA , KleinTE, DongBJ, PirmohamedM, HaasDW, KroetzDL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther.91(4) , 734–738 (2012).
  • Relling MV , GardnerEE, SandbornWJ et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3) , 387–391 (2011).
  • Relling MV , KleinTE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther.89(3) , 464–467 (2011).
  • Otlowski M , TaylorS, BombardY. Genetic discrimination: international perspectives. Annu. Rev. Genomics Hum. Genet.13 , 433–454 (2012).
  • Gerdes LU , GerdesC, KervinenK et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the scandinavian simvastatin survival study. Circulation 101(12) , 1366–1371 (2000).
  • Keene CD , CudabackE, LiX, MontineKS, MontineTJ. Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer‘s disease. Curr. Opin. Neurobiol.21(6) , 920–928 (2011).
  • O‘Donnell PH , BushA, SpitzJ et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92(4) , 446–449 (2012).
  • Bloss CS , SchorkNJ, TopolEJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N. Engl. J. Med.364(6) , 524–534 (2011).
  • Resta RG . Defining and redefining the scope and goals of genetic counseling. Am. J. Med. Genet. C Semin. Med. Genet.142C(4) , 269–275 (2006).
  • Crews KR , CrossSJ, McCormickJN et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am. J. Health Syst. Pharm. 68(2) , 143–150 (2011).
  • O‘Connor SK , FerreriSP, MichaelsNM et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics 13(8) , 955–962 (2012).
  • Nelen M , VeltmanJA. Genome and exome sequencing in the clinic: unbiased genomic approaches with a high diagnostic yield. Pharmacogenomics13(5) , 511–514 (2012).
  • Roberts JD , WellsGA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (rapid gene): a prospective, randomised, proof-of-concept trial. Lancet379(9827) , 1705–1711 (2012).
  • Hicks JK , CrewsKR, HoffmanJM et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin. Pharmacol. Ther. 92(5) , 563–566 (2012).
  • Beaulieu M , De Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics11(11) , 1573–1590 (2010).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.